Q-omics provides the consensus-scored KRT86 profile across patient tissues and cancer cell-line models. KRT86 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, KRT86 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, KRT86 RNA expression shows 13,501 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, THCA, and THYM as cancer lineages where KRT86 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT86 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT86 survival associations across molecular data types. KRT86 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT86 RNA expression–survival associations across cancer types. High KRT86 expression shows unfavorable associations in LUAD, OV and MESO, but favorable associations in SCLC, SKCM and HNSC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for KRT86 RNA expression.
This table summarizes KRT86 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT86. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT86 shows lower tumor expression in THCA and higher tumor expression in LUAD, KIRP, KIRC, LIHC and COAD. The THCA box plot shows higher KRT86 RNA expression in normal versus tumor tissue (log2 FC = −1.285, t-test p < 0.001).
This table shows molecular features associated with KRT86 in patient tissues and cancer cell lines. In patient samples, KRT86 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT86 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
